BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31557072)

  • 1. An overview of the efficacy and safety of prucalopride for the treatment of chronic idiopathic constipation.
    Daniali M; Nikfar S; Abdollahi M
    Expert Opin Pharmacother; 2019 Dec; 20(17):2073-2080. PubMed ID: 31557072
    [No Abstract]   [Full Text] [Related]  

  • 2. Prucalopride: A Review in Chronic Idiopathic Constipation.
    Garnock-Jones KP
    Drugs; 2016 Jan; 76(1):99-110. PubMed ID: 26628294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of prucalopride in adults with chronic idiopathic constipation.
    Vijayvargiya P; Camilleri M
    Expert Rev Clin Pharmacol; 2019 Jul; 12(7):579-589. PubMed ID: 31096799
    [No Abstract]   [Full Text] [Related]  

  • 4. Prucalopride for the treatment of constipation: a view from 2015 and beyond.
    Bassotti G; Usai Satta P; Bellini M
    Expert Rev Gastroenterol Hepatol; 2019 Mar; 13(3):257-262. PubMed ID: 30791758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prucalopride succinate for the treatment of constipation: an update.
    Bassotti G; Gambaccini D; Bellini M
    Expert Rev Gastroenterol Hepatol; 2016; 10(3):291-300. PubMed ID: 26647167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation.
    Tack J; Corsetti M
    Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1327-35. PubMed ID: 22985444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New pharmacological treatment options for chronic constipation.
    Corsetti M; Tack J
    Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prucalopride (Motegrity) for chronic idiopathic constipation.
    Med Lett Drugs Ther; 2019 Jun; 61(1573):86-88. PubMed ID: 31170120
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral prucalopride in children with functional constipation.
    Winter HS; Di Lorenzo C; Benninga MA; Gilger MA; Kearns GL; Hyman PE; Vandeplassche L; Ausma J; Hoppenbrouwers M
    J Pediatr Gastroenterol Nutr; 2013 Aug; 57(2):197-203. PubMed ID: 23535761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prucalopride for the treatment of women with chronic constipation in whom standard laxative regimens have failed to provide adequate relief.
    Pennant M; Orlando R; Barton P; Bayliss S; Routh K; Meads C
    Health Technol Assess; 2011 May; 15 Suppl 1():43-50. PubMed ID: 21609652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prucalopride: a new drug for the treatment of chronic constipation.
    Tack J
    Expert Rev Gastroenterol Hepatol; 2009 Aug; 3(4):337-43. PubMed ID: 19673621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of severe chronic constipation: differential roles of conventional laxatives and the prucalopride prokinetic].
    Layer P; Dathe K; Dignass A; Faiss S; Galle P; Lerch MM; Malfertheiner P; Wehrmann T; Zeuzem S
    Z Gastroenterol; 2011 Aug; 49(8):969-70. PubMed ID: 21796580
    [No Abstract]   [Full Text] [Related]  

  • 14. Prucalopride: a review of its use in the management of chronic constipation.
    Keating GM
    Drugs; 2013 Nov; 73(17):1935-50. PubMed ID: 24194435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.
    Vigone B; Caronni M; Severino A; Bellocchi C; Baldassarri AR; Fraquelli M; Montanelli G; Santaniello A; Beretta L
    Arthritis Res Ther; 2017 Jun; 19(1):145. PubMed ID: 28633671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Some practical questions on chronic stipsis treatment with prucalopride].
    Bellacosa L; Cogliandro R; Cremon C; De Giorgio R; Barbara G; Stanghellini V
    Minerva Gastroenterol Dietol; 2014 Mar; 60(1):85-99. PubMed ID: 24632771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of prucalopride in adults and children with chronic constipation.
    Diederen K; Mugie SM; Benninga MA
    Expert Opin Pharmacother; 2015 Feb; 16(3):407-16. PubMed ID: 25539475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. prucalopride (Resolor°) and chronic constipation in men: Avoid in both men and women.
    Prescrire Int; 2016 Oct; 25(175):234. PubMed ID: 30645825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular Safety of Prucalopride in Patients with Chronic Constipation: A Multinational Population-Based Cohort Study.
    Gilsenan A; Fortuny J; Cainzos-Achirica M; Cantero OF; Flynn RWV; Garcia-Rodriguez L; Harding A; Kollhorst B; Karlsson P; Linnér L; MacDonald TM; Odsbu I; Plana E; Ruigómez A; Schink T; Ziemiecki R; Andrews EB
    Drug Saf; 2019 Oct; 42(10):1179-1190. PubMed ID: 31134512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled trial of prucalopride for severe chronic constipation.
    Camilleri M; Kerstens R; Rykx A; Vandeplassche L
    N Engl J Med; 2008 May; 358(22):2344-54. PubMed ID: 18509121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.